Global Leadership Initiative in Sarcopenia (GLIS)-defined sarcopenia increases the mortality of esophageal cancer patients after esophagectomy: A Chinese real-world cohort study

被引:0
|
作者
Huo, Zhenyu [1 ,2 ]
Luo, Siyu [1 ,2 ]
Chong, Feifei [1 ,2 ]
Tong, Ning [1 ,2 ]
Lu, Zongliang [1 ,2 ]
Zhang, Mengyuan [1 ,2 ]
Liu, Jie [3 ]
Fang, Chunshu [4 ]
Guo, Wei [4 ]
Li, Na [1 ,2 ]
Xu, Hongxia [1 ,2 ]
机构
[1] Third Mil Med Univ, Army Med Univ, Daping Hosp, Dept Clin Nutr, Chongqing, Peoples R China
[2] Chongqing Municipal Hlth Commiss, Key Lab Intelligent Clin Nutr & Transformat, Chongqing, Peoples R China
[3] Thirteenth Peoples Hosp Chongqing, Dept Clin Nutr, Chongqing, Peoples R China
[4] Third Mil Med Univ, Army Med Univ, Daping Hosp, Dept Thorac Surg, Chongqing, Peoples R China
关键词
Sarcopenia; GLIS; Global Leadership Initiative in Sarcopenia; Esophageal cancer; Mortality; PULMONARY COMPLICATIONS; PREDICTOR; QLQ-C30; TRENDS;
D O I
10.1016/j.nut.2024.112600
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Objectives: To assess the impact of the definition of the Global Leadership Initiative in Sarcopenia (GLIS) on mortality in esophageal cancer (EC) patients, postesophagectomy, within a Chinese cohort and to validate the effectiveness of a new GLIS framework in oncology. Methods: We performed an observational real-world cohort study in a single center at Daping Hospital of the Army Medical University in China, spanning from December 2014 to July 2022. We used the combined definition of muscle mass and muscle strength in a new GLIS framework for the diagnosis of sarcopenia. Potential covariates were identified through univariate and multivariate analyses. The association between GLIS-defined sarcopenia and mortality was estimated using Kaplan-Meier curves and Cox models. We also conducted stratified analyses to assess the stability of multivariable Cox models. Results: A total of 520 EC patients were included in the study, with a median follow-up of 48.7 months. A total of 229 EC patients (44.0%) were identified with GLIS-defined sarcopenia. Patients with GLIS-defined sarcopenia had significantly worse overall survival in Kaplan-Meier curves (log-rank P = 0.015). Age; sex; tumor, node, metastasis stage; blood glucose; bleeding volume in operation; and operating time were introduced as covariates in a fully adjusted Cox model. Multivariable-adjusted Cox models revealed that GLIS-defined sarcopenia was an independent prognostic factor for EC patients postesophagectomy (hazard ratio, 1.87, 95% confidence interval, 1.28-2.74, P = 0.001). Stratified analyses confirmed the stability of the relationship between GLIS-defined sarcopenia and mortality in EC patients. Conclusions: GLIS-defined sarcopenia is prevalent among Chinese EC patients and is linked to increased mortality risk postesophagectomy. This finding offers compelling evidence and serves as a valuable reference for the establishment of an operational definition of GLIS sarcopenia. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页数:10
相关论文
共 21 条
  • [11] Alectinib versus crizotinib as first-line treatment in patients with advanced ALK-mutated non-small cell lung cancer: a Chinese, real-world cohort study
    Zhang, Haoran
    Wu, Zhaozhen
    Zhang, Dongming
    Liu, Jia
    Lu, Tao
    Shi, Yuequan
    Gao, Xiaoxing
    Liu, Xiaoyan
    Feng, Xiaoyi
    Guo, Xiaobei
    Yu, Siyuan
    Zhao, Jing
    Chen, Minjiang
    Zhong, Wei
    Xu, Yan
    Hu, Ying
    Wang, Mengzhao
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [12] Length of Hospitalization and Mortality among Stroke Patients before and after the Implementation of a Specialized Unit: A Retrospective Cohort Study Using Real-World Data from One Reference Hospital in Southern Brazil
    Poll, Marcia
    Martins, Rodrigo Targa
    Anschau, Fernando
    Jotz, Geraldo Pereira
    HEALTHCARE, 2024, 12 (08)
  • [13] Survival and Recurrence Patterns in Patients With Stomach Adenocarcinoma Receiving Chemotherapy or Chemoradiotherapy After D2 Gastrectomy in a Tertiary Care Cancer Institute: A Retrospective Real-World Evidence Cohort Study
    Mitra, Swarupa
    Simson, David K.
    Gehani, Manish
    Barik, Soumitra
    Khurana, Ruparna
    Singh, Shivendra
    Talwar, Vineet
    Goel, Varun
    Khurana, Himanshi
    Mishra, Manindra
    Dewan, Abhinav
    Mukhi, M. Jwala
    ADVANCES IN RADIATION ONCOLOGY, 2023, 8 (06)
  • [14] Outcomes and prognosis of non-small cell lung cancer patients who underwent curable surgery: a protocol for a real-world, retrospective, population-based and nationwide Chinese National Lung Cancer Cohort (CNLCC) study
    Wang, Xin
    Liang, Yicheng
    Wang, Yuanzhuo
    Meng, Xiangzhi
    Zhou, Boxuan
    Xu, Zhenyi
    Wang, Hui
    Yang, Wenjing
    Li, Ning
    Gao, Yushun
    He, Jie
    BMJ OPEN, 2023, 13 (06):
  • [15] Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study
    Zhou, Meirong
    Wang, Shouman
    Wan, Nengbin
    Yuan, Songlin
    Hu, Xiongqiang
    Zhou, Wei
    Qing, Bohua
    Liu, Mingwen
    Sun, Weihua
    Fan, Peizhi
    Wang, Jianguo
    Cao, Hong
    Xu, Haifan
    Dai, Bin
    Tang, Peizhi
    Qian, Liyuan
    Zhao, Xi
    Xiao, Jun
    Zhou, Huaiying
    Hu, Jinhui
    Ding, Li
    Tripodi, Domenico
    Zdenkowski, Nicholas
    O'Keefe, Thomas J.
    Sanchez, Alejandro Martin
    Chen, Li
    Zhang, Ping
    Xu, Feng
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (24)
  • [16] Real-world hospital costs for nonchemotherapy drugs and nondrug care associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small-cell lung cancer in Chinese patients: a retrospective cohort study
    Chen, Jianhua
    Wu, Shengqi
    Hu, Chenping
    Yang, Yicheng
    Rajan, Narayan
    Chen, Yun
    Yang, Canjuan
    Li, Jianfeng
    Chen, Wendong
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2016, 8 : 97 - 111
  • [17] Real-world survey of pneumonitis/radiation pneumonitis among patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy after durvalumab approval: A multicenter retrospective cohort study (HOPE-005/CRIMSON).
    Saito, Go
    Oya, Yuko
    Taniguchi, Yoshihiko
    Kawachi, Hayato
    Fujimoto, Daichi
    Matsumoto, Hirotaka
    Iwasawa, Shunichiro
    Suzuki, Hidekazu
    Niitsu, Takayuki
    Miyauchi, Eisaku
    Yokoi, Takashi
    Mitsui, Miho
    Uenami, Takeshi
    Sakata, Yoshihiko
    Arai, Daisuke
    Okada, Asuka
    Hara, Satoshi
    Teraoka, Shunsuke
    Kokubo, Masaki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [18] Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study
    Zhang, Dongming
    Liu, Xiaoyan
    Shen, Fangfang
    Zhao, Dahai
    Shi, Yuequan
    Zhang, Haoran
    Liu, Jia
    Gao, Xiaoxing
    Chen, Minjiang
    Zhao, Jing
    Zhong, Wei
    Gao, Junzhen
    He, Min
    Liu, Yonggang
    Yang, Xiaoling
    Qin, Jianwen
    Tang, Yuling
    Mu, Xinlin
    Gu, Yangchun
    Zhang, Shucai
    Chen, Xueqin
    Pang, Li
    Meng, Qingwei
    Guo, Ye
    Zhang, Yuhui
    Li, Wei
    Xing, Puyuan
    Cheng, Yuan
    Xin, Tao
    Li, Qingxia
    Li, Yu
    Chen, Jun
    Gao, Feng
    Jin, Bo
    Rossi, Antonio
    Adachi, Hiroyuki
    Guerrera, Francesco
    Husain, Hatim
    Xu, Yan
    Wang, Mengzhao
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (11) : 2229 - +
  • [19] Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: A Chinese, multicenter, real-world cohort study
    Zhang, D.
    Liu, X.
    Shen, F.
    Zhao, D.
    Shi, Y.
    Zhang, H.
    Liu, J.
    Gao, X.
    Chen, M.
    Zhao, J.
    Zhong, W.
    Xu, Y.
    Wang, M.
    ANNALS OF ONCOLOGY, 2023, 34
  • [20] Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
    Fujimoto, D.
    Takiguchi, Y.
    Matsumoto, S.
    Yamamoto, N.
    Saito, G.
    Nishimura, Y.
    Sugiyama, S.
    Oku, A.
    Karia, P.
    Antunes, L.
    Chapaneri, J.
    Salomonsen, R. J-B.
    Martin, E.
    Okhuoya, P.
    Muto, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1657 - S1658